Synthesis of Novel N-(4-benzoylphenyl)-2-furamide Derivatives and their Pharmacological Evaluation as Potent Antihyperlipidemic Agents in Rats

Abstract

In the search for new potential antihyperlipidemic agents, the present study focuses on the synthesis and pharmacological activity of a series of novel N-(4-benzoylphenyl)-2-furamides (3a–3e). Hyperlipidemia was induced in rats by single intraperitoneal injection of Triton WR-1339 (300 mg/kg body weight). At a dose of 15 mg/kg body weight, compounds 3b, 3d and bezafibrate (100 mg/kg) significantly (p<0.0001) reduced elevated plasma triglyceride levels after 18 h compared to the hyperlipidemic control group. However, only groups treated with compounds 3b, and 3d obviously showed a significant (p<0.0001) reduction in plasma total cholesterol levels. Moreover, high density lipoprotein-cholesterol levels were significantly (p<0.0001) increased in animals treated with compounds 3b, 3d and bezafibrate. It is therefore reasonable to assume that compounds 3b and 3d may have promising potential in the treatment of hyperlipidemia. This beneficial activity may contribute to their cardioprotective and antiatherosclerotic role.

Key words

Triton WR-1339-induced hyperlipidemic rats - N-(4-benzoylphenyl)-2-furamide - antihypertriglyceridemic - antihypercholesterolemic effect.

• References

• 1 Watts G.F, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high risk cardiovascular patient. Heart 2011; 97: 350-356
• 2 Sharma SK, Mishra HK, Sharma H et al. Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP levels in patients with sleep-disordered breathing in Delhi. Sleep Med 2008; 9: 149-156
• 3 Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-516
• 4 Ross R. Atherosclerosis – an inflammatory disease. New Engl J Med 1999; 340: 115-126
• 5 Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl J Med 1987; 317: 1237-1245
• 6 Raza JA, Babb JD, Movahed A. Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. Int J Cardiol 2004; 97: 355-366
• 7 Martin MJ, Hulley SB, Browner WS et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 2: 933-936
• 8 Aliasgarzadeh A, Ghorbanian M, Naghavi-Behzad M. Familial dysbetalipoproteinaemia presenting with cauliflower xanthoma. Niger Med J 2013; 54: 268-270
• 9 West KM, Ahuja MS, Bennet PH. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983; 6: 361-369
• 10 Hayashi H, Niinobe S, Matsumoto Y et al. T. Suga, Effects of Triton WR-1339 on lipoprotein lipolytic activity and lipid content of rat liver lysosomes. J Biochem 1981; 89: 573-579
• 11 Anandhi R, Annadurai T, Anitha TS et al. Antihypercholesterolemic and antioxidative effects of an extract of the oyster mushroom, Pleurotus ostreatus, and its major constituent, chrysin, in Triton WR-1339-induced hypercholesterolemic rats. J Physiol Biochem 2013; 69: 313-323
• 12 Al-Qirim T, Shattat G, Sweidan K et al. In Vivo Antihyperlipidemic Activity of a New Series of N-(Benzoylphenyl) and N-(Acetylphenyl)-1-benzofuran-2-carboxamides in Rats. Archiv der Pharmazie 2012; 345: 401-406
• 13 Shattat G, Al-Qirim T, Abu Sheikha G et al. The Pharmacological effects of novel 5-fluoro-N-(9,10-dihydro-9,10-dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats. J Enz Inhib Med Chem 2013; 28: 863-869
• 14 Kellner A, Correll JW, Ladd AT. Sustained hyperlipidemia induced in rabbits by means of intravenously injected surface active agents. J Exp Med 1951; 93: 373-384
• 15 Fiser RH, Denniston JC, Rindsig RB et al. Triglyceride secretion rates: use of Triton in the rhesus monkey. J Nutr 1974; 104: 223-226
• 16 Li YY, Jiang CJ, Wan XC et al. Purification and partial characterization of b-Glucosidase from fresh leaves of tea plants (Camellia sinensis (L) O.Kuntze. Acta Biochim Biophys Sin 2005; 37: 364-370
• 17 Harbowy ME, Balentine DA. Tea chemistry. Crit Rev Plant Sci 1997; 16: 415-480
• 18 Otway S, Robinson DS. The effect of the non-ionic detergent (Triton) on the removal of triglyceride fatty acids from the blood of the rats. J Physiol 1967; 190: 309-319
• 19 Fiser RH, Denniston JC, Rindsig RB et al. Triglyceride secretion rates: Use of Triton in the rhesus monkey. J Nutr 1974; 104: 223-226
• 20 Schurr PE, Schultz JR, Parkinson TM. Triton induced hyperlipidaemia in rats as an animal model for screening hypolipideamic drugs. Lipids 1972; 7: 69-74
• 21 Stanley G. Rapid increase in hepatic HMG CoA reductase activity and in vivo cholesterol synthesis after Triton WR 1339 injection. J Lipid Res 1978; 19: 1450-1461
• 22 Mitropoulos KA, Miller GJ, Howarth DJ et al. The effects of intravenous Triton WR-1339 on factor VII coagulant activity and plasma lipoproteins in normocholesterolaemic and hypercholesterolaemic rabbits. Blood Coagul Fibrinolysis 1994; 5: 583-591
• 23 Souliman A, Hicham H, Dounia G et al. Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract. J Ethnopharmacol 2009; 125: 157-162
• 24 Hayashi H, Niinobe S, Matsumoto Y et al. Effects of Triton WR-1339 on lipoprotein lipolytic activity and lipid content of rat liver lysosomes. J Biochem 1981; 89: 573-579
• 25 Yamamoto K, Shen B, Zarins C et al. In vitro and in vivo interactions of Triton 1339 with plasma lipoproteins of normolipidemic rhesus monkeys. Preferential effects on high density lipoproteins. Arteriosclerosis 1984; 4: 418-434
• 26 Ghatak A, Asthana OP. Recent trends in hyperlipoproteinemias and its pharmacotherapy.. Indian J Pharmacol 1995; 27: 14-29
• 27 Anila L, Vijayalakshmi NR. Flavonoids from Emblica officinalis and Mangifera indica-effectiveness for dyslipidemia. J Ethnopharmacol 2002; 79: 81-87
• 28 Khanna AK, Rizvi F, Chander R. Lipid lowering activity of Phyllanthus niruri in hyperlipemic rats. J Ethnopharmacol 2002; 82: 19-22
• 29 Malloy MJ, Kan JP. Medical-management of hyperlipidemic states. Adv Int Med 1994; 39: 603-631
• 30 Staels B, Dallongville J, Auwerx J et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093
• 31 Abu Sheikha G, Hussin B, Al-Hiari Y et al. Synthesis of benzothiophene carboxamide derivatives and their pharmacological evaluation as potent antihypertriglyceridemic agents in rats. Z Naturforsch C 2011; 66c: 93-103
• 32 Tremblay-Mercier J, Tessier D, Plourde M et al. Bezafibrate mildly stimulates ketogenesis and fatty acid metabolism in hypertriglyceridemic subjects. J Pharmacol Exp Ther 2010; 334: 341-346
• 33 Cabrero A, Alegret M, Sánchez RM et al. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes 2001; 50: 1883-1890
• 34 Nagasawa T, Inada Y, Nakano S et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006; 536: 182-191
• 35 Van der Zijl NJ, Goossens GH, Moors CC et al. Ectopic fat storage in the pancreas, liver, and abdominal fat depots: impact on β-cell function in individuals with impaired glucose metabolism. J Clin Endocrinol Metab 2011; 96: 459-467
• 36 Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L et al. Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet. Pancreas 2009; 38: e80-e86